Camrelizumab Combined With CRT for First-line Treatment of Patients With Local Recurrence of Esophageal Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- 57
Summary
- Conditions
- Esophageal Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
This is an open clinical study to evaluate the efficacy and safety of Camrelizumab combined with Concurrent Radiotherapy and Chemotherapy in the first-line treatment of locally recurrent esophageal cancer. Objective to study patients with local recurrence of esophageal cancer after radical treatment...
This is an open clinical study to evaluate the efficacy and safety of Camrelizumab combined with Concurrent Radiotherapy and Chemotherapy in the first-line treatment of locally recurrent esophageal cancer. Objective to study patients with local recurrence of esophageal cancer after radical treatment. The study will take progression free survival (PFS) as the main efficacy index, and plan to enroll about 236 patients with local recurrence of esophageal cancer after radical treatment. After fully informed and signed the informed consent, the subjects will enter the experimental stage after screening.
Tracking Information
- NCT #
- NCT04390945
- Collaborators
- Not Provided
- Investigators
- Not Provided